Tuesday, May 25, 2021 6:58:39 PM
2021-05-25 06:53:41 PM ET (Reuters)
May 25 (Reuters) - Nabriva Therapeutics PLC:
* SINOVANT SCIENCES AND NABRIVA THERAPEUTICS ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF LEFAMULIN IN CHINESE ADULTS WITH COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP)
* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS GENERALLY SAFE AND WELL-TOLERATED IN CHINESE ADULTS
* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS SHOWN TO BE NON-INFERIOR TO MOXIFLOXACIN
* NABRIVA THERAPEUTICS PLC - GREATER CHINESE RIGHTS TO LEFAMULIN WILL BE HELD BY SUMITOMO PHARMACEUTICALS (SUZHOU) CO., LTD., Source text for Eikon: Further company coverage:
I use both Fundamental and Technical Analysis.
Opinions posted by me are just that, my opinion.
Buy/sell any type of financial security is the sole
decision of the individual. Make your own sound
judgement or consult a professional licensed
advisor.
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM